Jenette Creaney

Summary

Affiliation: University of Western Australia
Country: Australia

Publications

  1. Sneddon S, Leon J, Dick I, Cadby G, Olsen N, Brims F, et al. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene. 2015;563:103-5 pubmed publisher
    ..No exonic germline BAP1 mutations of known functional significance were observed, further supporting the notion that sporadic germline BAP1 mutations are not relevant to the genetic susceptibility of MM. ..
  2. Sneddon S, Dick I, Lee Y, Musk A, Patch A, Pearson J, et al. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer. 2018;119:64-70 pubmed publisher
    ..Pleural effusion tumour cells provide an opportunity for the monitoring of tumour dynamics, treatment response and the clonal evolution of MM tumours. ..
  3. Creaney J, Dick I, Dare H, Demelker Y, Nowak A, Musk A, et al. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?. Lung Cancer. 2013;80:39-44 pubmed publisher
    ..We therefore conclude that binding of mesothelin to CA125 does not alter the measurement of mesothelin for the detection of MM. ..
  4. Creaney J, Dick I, Segal A, Musk A, Robinson B. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82:491-8 pubmed publisher
    ..Tumour biomarkers are being intensely investigated in MM as aids to diagnosis and prognosis. Hyaluronic acid (HA) is produced in MM but its role in prognostication remains uncertain...
  5. Robinson C, Dick I, Wise M, Holloway A, Diyagama D, Robinson B, et al. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer. 2015;15:983 pubmed publisher
    ..Of particular note, MexTAg mesothelioma development was not dependent on cdkn2 deletion. ..
  6. Creaney J, Robinson B. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment. Chest. 2017;152:143-149 pubmed publisher
  7. Creaney J, Dick I, Leon J, Robinson B. A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. Cancer Genomics Proteomics. 2017;14:103-117 pubmed
    ..The MM cell secretome is enriched in proteins that are likely to enhance its growth and response to stress and help it inhibit an adaptive immune response. These are potential targets for therapeutic and biomarker discovery. ..
  8. Sneddon S, Patch A, Dick I, Kazakoff S, Pearson J, Waddell N, et al. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer. 2017;17:396 pubmed publisher
  9. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber D, et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17:386 pubmed publisher
    ..Molecular markers like calretinin and mesothelin are promising tools to improve and supplement the diagnosis of MM and warrant further validation in a prospective study. ..